Literature DB >> 8874502

The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.

T J Palker1, A J Muir, D E Spragion, H F Staats, A Langlois, D C Montefiori.   

Abstract

Antisera to 21 synthetic peptides containing hydrophilic sequences of simian immunodeficiency virus strain mac251 (SIVmac251) gp120 and gp32 were tested for the ability to neutralize SIVmac251. Goat antisera raised to peptides SP-1 and SP-1V containing the carboxy-terminal portion of the V3 domain of SIVmac251 gp120 between amino acids 327 and 339 inhibited syncytium formation (90% inhibition at a 1/1024 dilution) and cell killing of CEMx174 cells by SIVmac251 (50%) inhibition of cell killing at a dilution of 1/5832), SIVDeltaB670 (1/568), and SIVsmH4 (1/740). Neutralizing antibodies to SIVmac251, SIVDeltaB670, and SIVsmH4 could be adsorbed by peptides containing a neutralizing V3 sequence of SIVmac251 gp120 (GLVFHSQPIND, amino acids 329-339) but not by peptides lacking this sequence. This V3 neutralizing region corresponds to a homologous V3 neutralizing site within HIV-2 gp120 reported by Björling et al. 1991, Proc. Natl. Acad. Sci. USA 88, 6082-6086, 1994, J. Immunol. 152, 1952-1959). Antibodies in 20 of 31 sera obtained from rhesus macaques infected with SIVmac251 reacted with a peptide containing the entire V3 sequence of SIVmac251 gp120, whereas no sera contained antibodies reacting with the V3 neutralizing site between amino acids 329 and 339. Low levels of antibody-mediated recognition and subsequent lack of selective pressure against this linear V3 neutralizing site might in part explain why this region is not a dominant neutralizing site and also why sequences within V3 do not vary during the course of SIV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874502     DOI: 10.1006/viro.1996.0548

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.

Authors:  H Petry; K Pekrun; G Hunsmann; E Jurkiewicz; W Lüke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

Authors:  E Jurkiewicz; G Hunsmann; J Schäffner; T Nisslein; W Lüke; H Petry
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  High major histocompatibility complex-unrestricted lysis of simian immunodeficiency virus envelope-expressing cells predisposes macaques to rapid AIDS progression.

Authors:  C Yin; M S Wu; C D Pauza; M S Salvato
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.

Authors:  R E Means; T Matthews; J A Hoxie; M H Malim; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.

Authors:  Seth A Faith; Yingyun Wu; David Kuhrt; Jonathan D Steckbeck; Jodi K Craigo; Janice E Clements; Kelly Stefano Cole
Journal:  Virology       Date:  2010-02-11       Impact factor: 3.616

8.  Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.

Authors:  Rosemarie D Mason; Hugh C Welles; Cameron Adams; Bimal K Chakrabarti; Jason Gorman; Tongqing Zhou; Richard Nguyen; Sijy O'Dell; Sabrina Lusvarghi; Carole A Bewley; Hui Li; George M Shaw; Zizhang Sheng; Lawrence Shapiro; Richard Wyatt; Peter D Kwong; John R Mascola; Mario Roederer
Journal:  PLoS Pathog       Date:  2016-04-11       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.